IRB #

STUDY00015597

Title

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versusPlacebo in Subjects with High Risk Invasive Urothelial Carcinoma

Principal Investigator

Jeremy Cetnar

Study Purpose

The purpose of this study is to compare any good and bad effects of using nivolumab (study drug) in urothelial carcinoma. The study drug could prevent your cancer from returning but it could also cause side effects. This study will allow the researchers to know how well the drug works.

Medical Condition(s)

Urothelial carcinoma which includes cancers of the urinary bladder, ureter & parts of the kidney.

Eligibility Criteria

1) At least 18 years of age
2) Confirmed cases of urothelial carcinoma
3) Needs to have your cancer removed by surgery within the last 3 months and be currently disease free

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

You will receive study drug for up to a period of one year. There will be follow-up examinations (without study drug) for a maximum of five years.

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Bristol-Myers Squibb

Recruitment End

12/31/2017

Compensation Provided

No


Go Back